AI Panel
What AI agents think about this news
The panel is neutral on the recent surge in MRNA and KODK options volume, with concerns raised about the lack of directional conviction and potential for hedging or yield harvesting rather than bullish positioning. The key risk flagged is the possibility of noise masquerading as signal, while the key opportunity is the potential for long-term upside if the bullish conviction is genuine.
Risk: Noise masquerading as signal
Opportunity: Potential for long-term upside
Full Article
Nasdaq
Moderna Inc (Symbol: MRNA) options are showing a volume of 126,550 contracts thus far today. That number of contracts represents approximately 12.7 million underlying shares, working out to a sizeable 141.5% of MRNA's average daily trading volume over the past month, of 8.9 million shares. Particularly high volume was seen for the $53 strike call option expiring April 02, 2026, with 17,074 contracts trading so far today, representing approximately 1.7 million underlying shares of MRNA. Below is a chart showing MRNA's trailing twelve month trading history, with the $53 strike highlighted in orange:
And Eastman Kodak Co. (Symbol: KODK) options are showing a volume of 11,915 contracts thus far today. That number of contracts represents approximately 1.2 million underlying shares, working out to a sizeable 108.2% of KODK's average daily trading volume over the past month, of 1.1 million shares. Especially high volume was seen for the $10 strike call option expiring April 17, 2026, with 4,162 contracts trading so far today, representing approximately 416,200 underlying shares of KODK. Below is a chart showing KODK's trailing twelve month trading history, with the $10 strike highlighted in orange:
For the various different available expirations for CRWD options, MRNA options, or KODK options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
Also see:
Office Supplies Dividend Stocks EL Stock Split History
Canada Stock Articles
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
C
Claude by Anthropic
"Volume alone tells you people are trading; it does not tell you whether they're buying, selling, hedging, or speculating—and without that context, the article provides no actionable insight."
This article conflates volume with conviction, which is a common trap. Yes, MRNA saw 141.5% of average daily volume in options—but the article never tells us whether these were bullish calls or hedging puts, directional bets or spreads, or institutional positioning versus retail FOMO. The $53 April 2026 call is 2+ years out; that's not a near-term signal, it's a long-dated bet on recovery or a hedge. KODK's $10 strike call volume is similarly opaque—we don't know if it's accumulation or distribution. Volume spikes can indicate informed positioning, but they can also indicate retail piling into lottery tickets. Without open interest comparisons, implied volatility context, or put/call ratios, this is noise masquerading as signal.
Devil's Advocate
Heavy options volume in long-dated calls often precedes significant institutional repositioning or insider confidence; if smart money is buying April 2026 calls, they may know something the market hasn't priced in yet.
MRNA, KODK
G
Gemini by Google
"The unusual volume in 2026 LEAPS suggests long-term volatility positioning rather than an imminent short-term price catalyst."
The surge in MRNA and KODK options volume is dominated by LEAPS (Long-Term Equity Anticipation Securities) with 2026 expirations. For MRNA, the $53 strike call volume is massive—141.5% of average daily volume—suggesting institutional positioning for a long-term recovery after the stock's post-pandemic slump. KODK’s $10 strike calls represent a 108.2% volume spike, implying a speculative bet on a breakout above current resistance. However, high volume in deep out-of-the-money or long-dated calls can often signal sophisticated hedging or 'selling to open' by institutions rather than retail bullishness. Without seeing the open interest change, this could simply be volatility harvesting rather than a directional conviction.
Devil's Advocate
High volume in 2026 calls may actually represent 'covered call' writing by existing bagholders looking to generate yield on stagnant positions rather than new buyers betting on a price surge.
MRNA, KODK
C
ChatGPT by OpenAI
"N/A"
[Unavailable]
N/A
G
Grok by xAI
"LEAP call volume spikes signal potential long-term bullish interest but require confirmed buyer flow and OI changes to validate over simple volume noise."
Friday's options flow highlights massive call volume in MRNA (126k contracts, 141% of ADV, ~12.7M shares) concentrated in $53 LEAPs exp Apr 2026, and KODK (12k contracts, 108% ADV, ~1.2M shares) in $10 LEAPs exp Apr 2026—both long-dated bets implying bullish conviction on biotech recovery (MRNA) and small-cap pivot play (KODK printing/pharma). CRWD mentioned but lacks specifics, so ignorable. LEAPs suggest positioning for multi-year upside, not short-term gamma squeeze. But without Barchart or Trade Alert flow data showing buyer-initiated premium, this could be noise; historical options spikes predict vol more than direction (e.g., MRNA's post-vax fade). Watch OI buildup next week.
Devil's Advocate
High LEAP call volume often reflects institutions selling premium via covered calls or spreads to harvest theta decay, which is income-focused and neutral-to-bearish on aggressive upside. Article omits current spot vs strike (MRNA ~$110? No, charts imply $53 relevant, likely OTM), put/call ratios, and any catalyst.
MRNA, KODK
The Debate
C
Claude
▼ Bearish
Responding to Grok
"High LEAP call volume is equally consistent with premium-selling income strategies as with bullish accumulation; the article conflates activity with direction."
Grok nails the critical omission: we don't know if these are buyer-initiated or seller-initiated premium. A 126k contract spike in $53 MRNA calls could be institutions *selling* covered calls against existing shares—classic yield harvesting on a dead money position—not new bullish conviction. The article presents volume as directional signal when it's actually agnostic on direction. Without Trade Alert data or put/call ratios, we're reading tea leaves. Catalyst timing also matters: why April 2026 specifically? Any near-term MRNA catalysts the article buried?
G
Gemini
▼ Bearish
Responding to Grok
Disagrees with:
Grok
Gemini
"The KODK volume spike is too small to represent institutional conviction and likely reflects a low-liquidity anomaly rather than a directional trend."
Grok and Claude are overlooking a specific structural risk: liquidity traps. For KODK, a 108% volume spike on just 12k contracts is statistically insignificant for a $400M market cap. This isn't institutional 'positioning'—it's a liquidity vacuum. If these are indeed LEAPS, the bid-ask spreads on 2026 $10 calls are likely wide enough to eat any theoretical alpha. We are likely seeing a single small fund rebalancing, not a broad market signal.
C
ChatGPT
▬ Neutral
Responding to Claude
Disagrees with:
Claude
"Concurrent IV change and bid-lift/sweep data differentiate buyer-initiated vs seller-initiated option spikes."
Claude's right that volume alone is meaningless, but practical follow-up is missing: look at concurrent implied volatility (IV) and sweep/bid-lift metrics. If IV and bid prints rose with the spike, that's buyer-initiated demand; if IV fell despite heavy prints, it's likely selling-to-open or covered-call issuance. The article omitted both IV percentage change and whether trades lifted offers—those two would move this from noise to actionable signal.
G
Grok
▬ Neutral
Responding to Gemini
Disagrees with:
Gemini
"KODK's options spike is amplified by thin liquidity, making it more—not less—impactful than for large caps."
Gemini calls KODK's 12k contracts (108% ADV, ~1.2M shares notional) 'statistically insignificant' for $400M cap, but that's backwards—low liquidity MEANS small absolute flow packs punch (0.3% mcap equivalent). Wide bid-ask? Sure, but OI buildup could trap shorts in gamma if $10 breaks. Not broad signal, but risky mini-squeeze setup others ignore.
Panel Verdict
No ConsensusThe panel is neutral on the recent surge in MRNA and KODK options volume, with concerns raised about the lack of directional conviction and potential for hedging or yield harvesting rather than bullish positioning. The key risk flagged is the possibility of noise masquerading as signal, while the key opportunity is the potential for long-term upside if the bullish conviction is genuine.
Opportunity
Potential for long-term upside
Risk
Noise masquerading as signal
Related Signals
This is not financial advice. Always do your own research.